Longevity Peptide Dosage Protocols

Open Protocolarrow_forward Pancreas Bioregulator

Suprefort (Pancreas Cytomax A-1) is a natural peptide bioregulator from Professor Vladimir Khavinson's St. Petersburg school of "cytomax" preparations: a low-molecular-weight peptide complex (standardized as "peptide complex A-1") extracted from the pancreas of young animals and marketed as a pancreas-supporting dietary supplement. Like other Khavinson bioregulators, its proposed mechanism is epigenetic rather than receptor-driven, short peptides that penetrate cells and interact with tissue-specific gene-promoter regions to restore age-impaired protein synthesis in pancreatic tissue. Most mechanistic and animal evidence comes from the synthetic pancreatic tetrapeptide analog Lys-Glu-Asp-Trp (KEDW, "Pancragen"), which upregulates pancreatic differentiation genes such as PDX1, PAX6 and FOXA2 in cell culture. The most commonly published Suprefort dosage is 1-2 capsules (10-20 mg of peptide complex A-1) taken once or twice daily, 30 minutes before meals, over a 10-30 day course repeated every 3-6 months. Suprefort is a peptide bioregulator (cytomax) class supplement; in real-world use it is taken ORALLY as 10 mg gelatin capsules, so the subcutaneous reconstitution figures on this page are an educational measurement reference only. Regulatory status is important: Suprefort is sold as a dietary supplement and is NOT approved as a drug by the FDA or EMA, and there are no large registered randomized controlled trials of the finished product in humans. This page is educational and is not medical advice.

Pancragen

Pancragen (KEDW) is a synthetic tetrapeptide bioregulator with the sequence Lys-Glu-Asp-Trp (about 576 Da), developed within Vladimir Khavinson's short-peptide "cytogen" program at the St. Petersburg Institute of Bioregulation and Gerontology and patented as a "tetrapeptide regulating blood glucose level in diabetes mellitus" [8]. Like other Khavinson cytogens, it is hypothesized to act not on a cell-surface receptor but by entering the nucleus and binding short ACCT-containing promoter motifs, where it up-regulates pancreatic differentiation transcription factors such as PDX1, PAX6, NGN3, FOXA2 and NKX2-2 [4][7]. Preclinical work reports modulated apoptosis of insulin-producing cells in streptozotocin-diabetic rats [1], restored glucose tolerance and normalized insulin and C-peptide dynamics in aged rhesus monkeys [3], and reduced p53-driven apoptosis with improved proliferation in aging pancreatic cell cultures [2]. A small human study embedded in the founding patent gave 10 mcg intramuscularly daily or 100 mcg orally twice daily and reported lower insulin requirements in type 1 and type 2 diabetics [8]. The most-cited Pancragen dosage in consumer protocols is roughly 200 mcg per day orally, or an educational 0.5-2 mg subcutaneous reference reconstituted from a 20 mg research vial, run as 10-day courses two to three times a year. Pancragen is not approved by the FDA or EMA and remains an investigational research compound only.

Stamakort

Open Protocolarrow_forward Liver Peptide Bioregulator

Stamakort (alias Gastric Cytomax, "A-10") is a Khavinson gastric-mucosa peptide bioregulator — a "cytomax" complex of short, low-molecular-weight peptides extracted from the gastric mucosa of young calves at the St. Petersburg Institute of Bioregulation and Gerontology. Like other Khavinson short peptides, it is proposed to act as a tissue-specific signal: small enough to enter cells and the nucleus, it is hypothesized to bind gene-promoter regions and modulate transcription, thereby supporting normal proliferation, differentiation, and barrier function of gastric epithelial and parietal cells rather than acutely blocking acid the way a proton-pump inhibitor does. The headline Stamakort dosage is 1-2 oral capsules (10-20 mg) once daily, 10-15 minutes before meals, for a 30-day course that is typically repeated two to three times per year; an educational subcutaneous reconstitution model on this page maps that onto roughly 250-1,000 mcg/day. Stamakort is sold mainly as an oral capsule, with a sublingual drop form also available. The peptide's amino-acid sequence is proprietary, its pharmacokinetics and half-life are not formally characterized, and independent randomized clinical evidence is essentially absent — most data come from the Khavinson group's own gerontological literature. Regulatory status: Stamakort is not approved by the FDA or EMA; it is registered in Russia and several CIS countries as a dietary supplement (BAA) and is offered elsewhere as a research or nutraceutical product. This page is educational and not medical advice.

Svetinorm

Open Protocolarrow_forward Thyroid Bioregulator

Svetinorm (also sold as Liver Cytomax A-7) is a natural liver peptide bioregulator from the Khavinson cytamin family: a tissue-specific complex of short peptides and free amino acids extracted from the livers of young calves and pigs at the St. Petersburg Institute of Bioregulation and Gerontology [1][2]. Like other cytamins, it is proposed to act as a hepatocyte-directed gene-expression regulator rather than a receptor ligand, with small peptide fractions reaching the nucleus to modulate transcription of liver-maintenance, antioxidant, and protein-synthesis genes [1][3]. Russian experimental work on liver polypeptide complexes reports normalized transaminases, restored antioxidant status, and faster recovery in models of toxic and chronic hepatitis, with the largest effects in aged animals [1]. The established Svetinorm dosage is oral: each capsule contains about 10 mg of the A-7 peptide complex, taken as 1-2 capsules once or twice daily with meals for a 30-day course, repeated every 3-6 months [8]. Svetinorm is marketed as a dietary supplement (cytamin) and is not approved as a drug by the FDA, EMA, or other major Western regulators; no randomized controlled human trials of the finished product exist. This page presents an educational subcutaneous reconstitution reference modeled on the injectable liver-cytomedin analog of this class, alongside the real-world oral protocol. It is reference information, not medical advice.

Thyreogen

Open Protocolarrow_forward Vascular Peptide Bioregulator

Thyreogen (also sold as Thyroid Cytomax A-2) is an orally administered Khavinson peptide bioregulator: a complex of low-molecular-weight peptide fractions (molecular weights up to about 5000 Da) isolated from the thyroid glands of young calves at the St. Petersburg Institute of Bioregulation and Gerontology [1][3]. As a tissue-specific "cytomax," it is proposed to act not on a cell-surface receptor but by delivering short regulatory peptides that enter thyroid cells and modulate transcription of genes governing thyrocyte metabolism, self-renewal, and the synthesis of T3, T4, and calcitonin [2]. The most commonly published Thyreogen dosage is 1-2 capsules (each containing 10 mg of peptide complex A-2) taken once or twice daily, 15-20 minutes before meals, for a one-month course repeated two to three times per year, which works out to roughly 10-40 mg of peptide complex per day by mouth [1]. Pharmaceutical-grade injectable counterparts of this thyroid cytomedin (for example Thyramin) have been studied in elderly residents of iodine-poor regions and in autoimmune thyroiditis, with reports of normalized thyroid indices and reduced autoantibody titres, though no large randomized controlled trials exist [1][3]. Thyreogen is not approved by the FDA or EMA as a drug; in Russia it is marketed as a dietary peptide supplement, and elsewhere it is sold for research and educational use only. The reconstitution and subcutaneous figures on this page are an educational modeling reference for the bioregulator class, not the product's real oral route. This is reference information, not medical advice.

Ventfort

scienceVial: 100 mg | 40 mg/mL

Ventfort is an oral Khavinson vascular peptide bioregulator, a "Cytomax" tissue complex (peptide complex A-3) extracted from the blood-vessel tissue of young calves at the St. Petersburg Institute of Bioregulation and Gerontology. Like other short-peptide bioregulators, it is proposed to act epigenetically rather than through a classical receptor: ultrashort peptides are reported to enter the cell nucleus and bind DNA promoter regions and histones, modulating tissue-specific gene expression [1]. In the vascular system, the corresponding synthetic tripeptide KED (Vesugen, Lys-Glu-Asp) is described in peer-reviewed work as a vasoprotective peptide derived from cattle vessels and has been reported to normalize endothelin-1 and restore endothelial proliferation markers in vitro [2]. The headline Ventfort dosage is 20 mg per day, taken as two 10 mg capsules with meals for a 30-day course, typically repeated every 4-6 months; some protocols use one to two capsules one or two times daily (about 10-40 mg/day). Clinical data come almost entirely from Khavinson's group and from small, mostly unblinded studies, with no large independent randomized trials. Ventfort is not approved by the FDA or EMA as a drug; in the United States it is sold only as a dietary supplement, and the reconstitution and half-life figures below are an educational reference, not medical advice.

Open Protocolarrow_forward Bronchopulmonary Bioregulator

Taxorest

Open Protocolarrow_forward Respiratory Bioregulator

Taxorest (bronchial Cytomax A-19) is a natural peptide bioregulator in Vladimir Khavinson's Cytomax line, a concentrated complex of low-molecular-weight peptides extracted from the bronchial mucosa of young animals and sold in 10 mg capsules for the bronchopulmonary system. Like the rest of the Khavinson tissue-specific peptide program, it is hypothesized to act as an epigenetic regulator that restores gene expression and protein synthesis in bronchial epithelial cells, normalizing ciliated-cell architecture, secretory IgA, and the pro-inflammatory cytokine balance [1][2]. Its synthetic tetrapeptide counterpart, Bronchogen (Ala-Glu-Asp-Leu), is the form used in most peer-reviewed laboratory work on chronic obstructive pulmonary disease and bronchial remodeling [1][3]. The headline Taxorest dosage is 20 mg per day (two capsules) taken before meals for a 10- to 30-day course and repeated every 3-6 months, with a practical range of 10-40 mg/day. Because it is an oral peptide complex, there is no validated subcutaneous dose; the reconstitution figures on this page are an educational reference that mirrors how the site presents other oral and topical compounds. Taxorest is not approved by the FDA or EMA; it is registered in Russia as a dietary supplement (biologically active food additive) and should be treated as a research/educational compound elsewhere. Evidence outside the Khavinson group is limited, and no independent randomized controlled trials have been published.

Bronchogen

Open Protocolarrow_forward Cardiac Bioregulator

Bronchogen (bronchial cytogen, AEDL) is a synthetic tetrapeptide bioregulator with the sequence Ala-Glu-Asp-Leu (molecular weight about 446.5 Da), developed within Vladimir Khavinson's short-peptide program at the St. Petersburg Institute of Bioregulation and Gerontology and protected under US Patent 7,625,870 as a "peptide substance restoring respiratory organs function" [1]. As a member of the Khavinson "cytogen" family, it is not thought to act on a cell-surface receptor; the prevailing hypothesis is that this small, charged peptide enters the nucleus of bronchial and alveolar cells and binds specific DNA promoter sequences, raising local DNA thermostability and modulating expression of genes that govern respiratory epithelial differentiation, mucin and surfactant production, and local immunity [2][4]. Preclinical rat studies report that a one-month course reduces COPD-type airway remodeling, restores ciliated cells, increases secretory IgA, and lowers neutrophilic inflammation [3][5]. Because no human clinical trials have been published, Bronchogen remains a research and educational compound with no FDA or EMA approval. The headline Bronchogen dosage in supplier and bioregulator protocols is roughly 1-2 mg per day subcutaneously from a 20 mg lyophilized vial across short 10-day courses repeated two to three times per year; an oral "Cytogen" capsule form (about 200-400 mcg/day for 10-30 days) is also marketed. This page presents an educational subcutaneous reconstitution reference for the Khavinson respiratory bioregulator class, not medical advice.

Chelohart

Open Protocolarrow_forward Testes Bioregulator

Chelohart (Heart Cytomax A-14) is a natural peptide bioregulator from Vladimir Khavinson's cytomax/cytomedin program at the St. Petersburg Institute of Bioregulation and Gerontology. Rather than a single defined sequence, it is a low-molecular-weight complex of peptide fractions (marketed as Peptide Complex A-14, generally under 5 kDa) extracted and purified from the cardiac muscle tissue of young calves, supplied as 10 mg oral capsules. Like other Khavinson bioregulators, it is hypothesized to act at the level of gene expression in cardiomyocytes, normalizing myocardial metabolism, supporting protein synthesis, and modulating cell renewal, rather than binding a classical surface receptor [1][2]. The most commonly cited Chelohart dosage is 10-20 mg per day (one to two 10 mg capsules, taken once or twice daily with meals), run as 30-day courses and repeated every 3-6 months; an intensive course uses 2 capsules per day for 30 days. Chelohart has no published human clinical trials of its own and is not approved by the FDA or EMA; it is sold as a dietary or research peptide supplement, and the evidence base rests on the broader Khavinson peptide-bioregulator literature [6][7]. This page presents the real oral dosing alongside an educational subcutaneous reconstitution reference (a modeling convention used across this site); the injectable milligram figures are illustrative only and are not a bioavailability-adjusted conversion of the capsule dose.

Testoluten

Open Protocolarrow_forward Ovary Peptide Bioregulator

Testoluten (Testes Cytomax A-13) is a natural peptide complex bioregulator isolated from the testicular tissue of young animals within Vladimir Khavinson's short-peptide program at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the "Cytomax" line of cytomedins, the natural counterparts of the synthesized "Cytogen" short peptides; the corresponding synthesized testes analog is the tetrapeptide Testagen (Lys-Glu-Asp-Gly, KEDG). Like the rest of the Khavinson family, it is not thought to act on a cell-surface receptor. The prevailing hypothesis is that the short, charged peptides it contains enter the cell nucleus and bind specific DNA promoter sequences, modulating expression of genes that govern Leydig-cell steroidogenesis and Sertoli-cell support of spermatogenesis rather than supplying testosterone or a gonadotropin signal. Mechanistic plausibility for the class comes from in-vitro nuclear-penetration and DNA-binding studies and from classic cytomedin organotypic-culture work, but testes-specific human evidence is limited to small Russian reports, and there are no Western randomized trials. Testoluten is sold as an oral 10 mg capsule and is not approved by the FDA or EMA; it is a dietary-supplement/research compound only. The headline Testoluten dosage is 1-2 capsules once or twice daily (about 10-20 mg/day) 30 minutes before food for a roughly one-month course repeated seasonally. This page also presents an educational subcutaneous reconstitution reference, since no injectable Testoluten exists.

Zhenoluten

Open Protocolarrow_forward Kidney Peptide Bioregulator

Zhenoluten (Ovary Cytomax A-15) is a Khavinson ovary peptide bioregulator: a natural complex of low-molecular-weight peptides (up to roughly 5000 Da) isolated from the ovarian tissue of young animals and developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson [1][3]. As a member of the "Cytomax" family it is not a single defined molecule but a tissue-specific peptide extract, proposed to enter ovarian cells and modulate transcription of genes that govern follicular and reproductive-cell maintenance rather than to bind a surface receptor [2][4]. A manufacturer clinical study report describes improvements in climacteric (menopausal) symptoms and partial restoration of menstrual function in women with exhausted ovary syndrome, alongside reductions in FSH and LH and a rise in estradiol after a 30-day course [1]. The most commonly cited Zhenoluten dosage is one 10 mg capsule taken twice daily by mouth (20 mg/day) for a 30-day intensive course, repeated as shorter 10-day maintenance courses two to three times per year [1]. Zhenoluten is sold as an oral capsule supplement and is not approved as a drug by the FDA or EMA; the subcutaneous reconstitution figures on this page are an educational measurement reference only, not a validated route or medical advice.

Pielotax

Open Protocolarrow_forward Retina Peptide Bioregulator

Pielotax (also sold as Kidney Cytomax A-9) is a Khavinson-class peptide bioregulator: a natural peptide complex (a "cytomax") isolated from the kidney tissue of young calves and marketed as a kidney-targeted dietary peptide rather than a synthetic single sequence. Like other Khavinson bioregulators, its short kidney-derived peptides are hypothesized to enter renal cells and modulate tissue-specific gene expression, supporting cell renewal and filtration function in the nephron [1][4]. Each capsule contains 10 mg of peptide complex A-9, and the standard real-world Pielotax dosage is oral: 1-2 capsules taken twice daily with meals (a 20-40 mg daily total) across a 15-30 day course, repeated after a 3-6 month interval [8]. Mechanistic and animal work from the St. Petersburg Institute of Bioregulation and Gerontology reports that calf-kidney polypeptide complexes raise the proliferation marker Ki-67, lower pro-apoptotic p53, and restore creatinine clearance, diuresis and glomerular filtration after experimental kidney injury [2][3][4]. A small 2011 manufacturer-affiliated study in gouty nephropathy reported improved urea and uric-acid markers with good tolerability [8]. Pielotax is not approved by the FDA or EMA; outside Russia it is sold as a supplement or research material only. This page presents an educational subcutaneous reconstitution reference for the kidney bioregulator class, while the clinical product itself is taken by mouth.

Visoluten

Open Protocolarrow_forward Bladder Peptide Bioregulator

Visoluten (Eye Cytomax A-11) is an oral retina peptide bioregulator from Vladimir Khavinson's short-peptide program at the St. Petersburg Institute of Bioregulation and Gerontology. It is a "cytomax" preparation: a complex of low-molecular-weight peptides extracted from the retinal tissue of young calves, supplied as 10 mg enteric capsules and marketed as research or nutraceutical support for the visual system. Mechanistically it is grouped with the Khavinson bioregulators, very short peptides proposed to enter cells, bind specific promoter and histone regions of DNA, and normalize tissue-specific gene expression and protein synthesis in retinal and pigment-epithelial cells [2][3][4]. Its injectable sibling Retinalamin and the synthetic tetrapeptide analog Epitalon (Ala-Glu-Asp-Gly) carry most of the retina-specific evidence, including improved electroretinographic activity in retinitis pigmentosa models and patients [1][3][5]. The most-cited Visoluten dosage is roughly 10-20 mg/day orally (two 10 mg capsules), taken in 10-30 day courses repeated two to three times per year; the subcutaneous reconstitution figures on this page (about 2.5-5 mg/day, modeled on the injectable retina peptide) are an educational reference only, because the real product is taken by mouth. No controlled human trials of Visoluten itself have been published, and it is not approved by the FDA or EMA for any indication; it is sold for research and educational use only. This page summarizes Visoluten dosage, reconstitution, mechanism, and safety as a factual reference, not medical advice.

Chitomur

scienceVial: 10 mg | 5 mg/mL

Chitomur (Bladder Cytomax A-12) is a natural peptide bioregulator in the Khavinson "Cytomax" family: a lyophilized complex of short, bladder-derived peptides (chains of roughly 2 to 4 amino acids) isolated from the urinary-bladder tissue of young animals at the St. Petersburg Institute of Bioregulation and Gerontology [2][3]. Rather than acting on a cell-surface receptor, these ultrashort peptides are hypothesized to enter the nucleus of bladder epithelial and detrusor smooth-muscle cells and bind tissue-specific promoter sequences, modulating the genes that govern bladder-wall regeneration, detrusor tone, and local antioxidant defense [2][4]. The strongest clinical signal is a blind, randomized, placebo-controlled study by Gomberg, Ryzhak, and Liutov (2013) in which a 30-day Chitomur course significantly improved urodynamic parameters and quality of life in elderly men with benign prostatic hyperplasia, with no adverse effects recorded [1]. The headline Chitomur dosage is oral: each capsule contains 10 mg of the peptide complex, taken as an "intensive" course of roughly 10 to 40 mg/day (1 to 4 capsules) for 30 days, followed by intermittent maintenance pulses every 2 to 3 months. Chitomur is not approved by the FDA or EMA as a drug; it is marketed as a dietary supplement and research bioregulator. Because this site standardizes on injectable reconstitution math, the subcutaneous figures below are an educational reference only, not a validated route for this orally dosed cytomax.

Open Protocolarrow_forward Bone-Marrow Peptide Bioregulator

Bonomarlot

Open Protocolarrow_forward Cartilage Peptide Bioregulator

Bonomarlot (Bone-marrow Cytomax A-20) is a Khavinson-class peptide bioregulator: a complex of short peptide fractions isolated from the bone marrow of young animals and marketed as an oral dietary supplement by the St. Petersburg Institute of Bioregulation and Gerontology lineage. Rather than acting on a single receptor, this family of ultrashort peptides is proposed to enter cell nuclei and bind tissue-specific promoter regions, modulating the expression of genes that govern proliferation and differentiation of hematopoietic and immune cells [1][2]. Bonomarlot is sold as 0.2 g capsules, and the most commonly cited Bonomarlot dosage is roughly 10-20 mg/day (1-2 capsules) taken with meals, run as a 20-30 day intensive course followed by short 10-day maintenance pulses every two to three months [8]. Because these are di-, tri-, and tetrapeptide complexes, free-peptide plasma half-life is very short (on the order of minutes), while the proposed gene-regulatory effect is thought to outlast plasma presence, which is the rationale for pulsed multi-week courses [1][6]. Evidence for the bioregulator class comes largely from Russian experimental and review literature describing lifespan extension and gene-expression effects in animals; rigorous, independently replicated human trials specific to Bonomarlot are lacking [3][4]. Bonomarlot is not approved by the FDA or EMA as a drug and is offered for research and educational use only; the subcutaneous reconstitution figures below are an educational measurement reference, not the real-world route.

Sigumir

Open Protocolarrow_forward Adrenal Peptide Bioregulator

Sigumir is a cartilage-and-bone peptide bioregulator (a "Cytomax") from the Khavinson family of short-peptide preparations, manufactured by the St. Petersburg Institute of Bioregulation and Gerontology from peptide fractions of young-animal cartilage and bone tissue. It is sold as the A-4 cartilage bioregulator (catalogued by some vendors as Cartilage Cytomax A-8) in 10 mg oral capsules. The proposed mechanism is epigenetic: ultrashort di- to tetra-peptides are thought to enter cells and the nucleus and bind tissue-specific promoter regions, normalising gene expression in chondrocytes and osteoblasts (collagen type II, SOX9, aggrecan, osteocalcin) [2][4][6]. The headline Sigumir dosage is 10-20 mg per day (1-2 capsules with meals) for a 30-day course, usually repeated two to three times yearly. Direct, independently published randomised trials of Sigumir itself are scarce; the supporting evidence is mechanistic plus a long-term St. Petersburg cohort of 266 elderly subjects given related thymus and pineal bioregulators, which reported lower mortality and fewer age-related disorders [1][5]. Sigumir is not approved by the FDA or EMA as a drug; in Russia and several other markets it is sold as a dietary supplement/parapharmaceutical, and elsewhere it is treated as research-use-only. The subcutaneous reconstitution model on this page (20 mg vial in 1.0 mL bacteriostatic water) exists only so the oral dose can be expressed in insulin-syringe units; the real route is oral. This page is an educational dosage reference, not medical advice.

Glandokort

Open Protocolarrow_forward Prostate Peptide Bioregulator

Glandokort (also sold as Adrenal Cytomax A-17) is an oral peptide bioregulator from Vladimir Khavinson's "cytomax" family, manufactured from purified bovine adrenal-cortex tissue at the St. Petersburg Institute of Bioregulation and Gerontology lineage of products [1]. As a cytomax it is a lyophilized complex of short, low-molecular-weight peptide fragments rather than a single synthetic sequence, and within the Khavinson framework it is proposed to act as a tissue-specific epigenetic regulator that supports the adrenal cortex and its output of cortisol, aldosterone, and adrenal androgens such as DHEA [1][2]. The standard Glandokort dosage is 20 mg per day, taken as two 10 mg capsules (1-2 capsules, 1-2 times daily) roughly 15-30 minutes before food, for a 30-day course that is typically repeated every 3-6 months, often with a shorter 10-day maintenance pulse. Because the real-world route is oral, the subcutaneous reconstitution figures below are an educational reference only, modelled the way this site presents other Khavinson bioregulators. Direct clinical-trial evidence for Glandokort as a finished product is limited; the supporting data come from Khavinson's broader short-peptide program and from related primate neuroendocrine studies showing normalization of age-disrupted cortisol rhythms [5][6]. Glandokort is not approved as a drug by the FDA or EMA and is marketed as a dietary supplement or research compound. Nothing here is medical advice.

Libidon

Open Protocolarrow_forward Parathyroid Peptide Bioregulator

Libidon (Prostate Cytomax A-16) is an oral peptide bioregulator from the Khavinson family of tissue-specific "cytomax" preparations developed at the St. Petersburg Institute of Bioregulation and Gerontology. Each capsule supplies 10 mg of peptide complex A-16, a low-molecular-weight fraction (under ~5,000 Da) of di-, tri- and tetrapeptides isolated from the prostate tissue of young cattle [4][8]. Rather than acting as a hormone or enzyme blocker, these ultrashort peptides are proposed to enter cells, reach the nucleus, and bind specific promoter regions of DNA, modulating tissue-specific gene expression and protein synthesis in prostate and immune cells [1][2]. The most-cited Libidon dosage is 20 mg per day, taken as one 10 mg capsule twice daily with meals across a 30-day course, with a lighter 10 mg/day option and a 10-day maintenance pulse repeated every 3-6 months [4]. In the originating institute's observation of 48 men with chronic prostatitis or benign prostatic hyperplasia, the course was associated with less pelvic pain, reduced urinary frequency, and improved flow [4], echoing decades of Russian urological use of related bovine prostate peptide preparations such as Prostatilen and Vitaprost [5][6][7]. Libidon is a bovine prostate peptide bioregulator of the cytomax class; it is not approved by the FDA or EMA as a drug and is sold as a dietary supplement or research material only. The subcutaneous reconstitution figures on this page are an educational measurement reference, since clinically Libidon is swallowed, not injected.

Bonothyrk

Open Protocolarrow_forward Cardiac Bioregulator

Bonothyrk (Parathyroid Cytomax A-21) is a Khavinson-class peptide bioregulator: a low-molecular-weight peptide complex extracted from calf parathyroid glands and standardized to about 10 mg of active peptides per capsule. Like other Cytomax/Cytogen bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology, it is proposed to act as a tissue-specific epigenetic signal rather than as parathyroid hormone replacement, with short peptides entering cell nuclei to modulate expression of parathyroid- and bone-related genes [2][3]. The headline Bonothyrk dosage in the manufacturer protocol is 1-2 capsules once or twice daily with meals, most commonly two 10 mg capsules per day (about 20 mg/day) for a 30-day course, repeated every 3-6 months [1]. Its real-world route is oral (a sublingual "lingual" version also exists); the subcutaneous reconstitution figures on this page are an educational measurement reference, not a clinical delivery method. Unlike defined synthetic Khavinson tripeptides such as Pinealon (Glu-Asp-Arg) or Epitalon (Ala-Glu-Asp-Gly), Bonothyrk has no single published amino-acid sequence, since it is a multi-fraction natural extract. Bonothyrk is not approved by the FDA or EMA for any disease; it is sold as a dietary supplement in Russia and as a research or educational supplement elsewhere. This page summarizes the Bonothyrk dosage, reconstitution model, mechanism, and the limited evidence base for educational purposes only.

Cardiogen

Cardiogen (CardioCytogen) is a synthetic tetrapeptide bioregulator with the sequence Ala-Glu-Asp-Arg (AEDR, molecular weight about 489.5 Da), developed within Vladimir Khavinson's short-peptide program at the St. Petersburg Institute of Bioregulation and Gerontology and protected under US Patent 7,662,789 as a "peptide substance restoring myocardium function" [1]. As a member of the Khavinson "cytogen" family, it is not believed to act on a cell-surface receptor; instead the prevailing hypothesis is that this small, charged peptide enters the cell nucleus and binds specific DNA promoter sequences, modulating expression of genes that govern cardiomyocyte and vascular-cell maintenance [2][4]. Preclinical reports attribute to AEDR stimulation of cardiac explant proliferation, reduced p53-driven apoptosis, and regulation of inflammaging and senescence markers in cardiovascular cells [3]. Because no human clinical trials of Cardiogen have ever been published, it is strictly a research and educational compound with no FDA or EMA approval. The headline Cardiogen dosage reported in supplier and research protocols is roughly 1-2 mg per day subcutaneously from a 20 mg lyophilized vial across short 10-day courses, repeated two to three times per year; an oral "Cytogen" capsule form (about 200-400 mcg/day for 10-30 days) is also marketed. This page presents an educational subcutaneous reconstitution reference for the Khavinson cardiac bioregulator class. It is not medical advice, and Cardiogen should be regarded as an investigational compound only.

Ovagen

Ovagen is a synthetic short-chain peptide bioregulator (Glu-Asp-Leu, EDL tripeptide) developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson as the active fragment isolated from bovine liver tissue extracts [1][2]. Within the Khavinson cytomedin framework, Ovagen is hypothesized to function as a hepatocyte-specific epigenetic modulator that enters the nucleus and binds to short, tissue-specific promoter sequences to upregulate hepatic protein synthesis, bile acid production, and antioxidant defense genes [2][3]. Preclinical and small Russian clinical observations describe normalization of transaminases, improved albumin synthesis, and accelerated recovery from toxic and viral hepatic insults [4][5]. Ovagen is not approved by the FDA, EMA, or other major Western regulators and is considered an unapproved investigational compound. Typical research dosing follows Khavinson convention: 1 to 2 capsules (each containing approximately 100 to 200 mcg of EDL with accompanying excipients) once or twice daily for 20 to 30 days, repeated every 4 to 6 months.

Testagen

Testagen is a synthetic tetrapeptide (Lys-Glu-Asp-Gly, KEDG) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as the active fragment isolated from bovine testicular tissue extracts [1][2]. It belongs to the family of Khavinson short-peptide bioregulators that are hypothesized to selectively penetrate the cells of the tissue of origin, enter the nucleus, and modulate the transcription of genes involved in steroidogenesis, spermatogenesis, and androgen receptor signaling [3]. Russian observational studies and animal models have described improvements in testosterone synthesis, sperm parameters, and prostatic function in models of chronic prostatitis [4]. Testagen is not FDA approved, is not authorized by any Western regulator, and is used only in research contexts. The conventional Khavinson dosing schedule is 1 to 2 oral capsules (each containing approximately 200 mcg of KEDG) twice daily for 20 to 30 days, repeated every 4 to 6 months, sometimes combined with other Khavinson bioregulators such as Prostamax (prostate) and Endoluten (pineal).

Vilon

Vilon is a synthetic dipeptide (Lys-Glu, KE) developed by Khavinson and colleagues as one of the shortest active peptide bioregulators, derived by directed synthesis from the amino acid composition of Thymalin, a bovine thymic extract used in Russian clinical immunology since the 1970s [1][2]. As a peptide of just two residues, Vilon represents the minimal active sequence in the Khavinson cytogen library and is investigated for thymic restoration, immune rejuvenation, and lifespan extension. In CBA mice receiving chronic Vilon administration starting at 6 months of age, Anisimov and Khavinson reported lifespan extensions of 20–40% with reduced spontaneous tumor incidence and improved immune markers [3]. Vilon is hypothesized to bind DNA directly through electrostatic complementarity of its Lys-Glu zwitterion to specific promoter sequences, modulating chromatin condensation and tissue-specific gene expression. Research dosing varies: 1–10 mcg/kg subcutaneously in animals, 100–500 mcg/day subcutaneously in research-community human use, or 1–10 mg/day orally in Russian bioregulator practice. Vilon is registered in Russia under bioregulator legislation but has no FDA, EMA, or MHRA approval.

scienceVial: Lys-Glu-Asp) (20 mg | 6.67 mg/mL

Vesugen

Vesugen is a synthetic tripeptide (Lys-Glu-Asp, KED) developed by Vladimir Khavinson and colleagues as a tissue-specific bioregulator targeting the vascular endothelium and broader cardiovascular system [1][2]. It is one of the Khavinson cytogen family, derived from analysis of the amino acid composition of vascular wall protein extracts and synthesized as a defined short-peptide bioregulator for endothelial gene-program modulation. Preclinical work documents binding to the MKI67 gene promoter and modulation of endothelin-1 (EDN1), connexin (GJA1/Cx43), and SIRT1 expression in vascular cells, supporting effects on endothelial proliferation, intercellular communication, and longevity-associated gene programs [3]. Research dosing is 100–500 mcg subcutaneously per day across 10–20 day cycles, or 1–10 mg/day orally in outpatient Russian bioregulator practice, repeated 2–4 times yearly. Vesugen is registered in Russia under peptide-bioregulator and dietary-supplement legislation but has no FDA, EMA, or MHRA approval. Human clinical evidence is limited to Russian observational use in age-related vascular disorders.

Cartalax

Cartalax is a synthetic tripeptide (Ala-Glu-Asp, AED) developed by Vladimir Khavinson and colleagues as a tissue-specific bioregulator targeting cartilage, chondrocytes, and musculoskeletal connective tissue [1][2]. Derived by directed synthesis from analysis of cartilage protein composition, Cartalax shares the AED motif with several other Khavinson peptides but is positioned within the cytogen library as cartilage-targeted on the basis of its preferential effects in chondrocyte cultures and fibroblast-derived musculoskeletal cell lines [3]. Preclinical work shows Cartalax reduces aging markers p16, p21, and p53 while increasing SIRT6, a longevity-associated histone deacetylase, in cartilage cultures. The peptide also activates extracellular matrix gene programs and reduces chondrocyte apoptosis under metabolic stress. Research dosing is 100–500 mcg subcutaneously per day across 10–20 day cycles, or 1–10 mg/day orally in outpatient Russian bioregulator practice. Cartalax is registered in Russia under peptide-bioregulator and dietary-supplement legislation but has no FDA, EMA, or MHRA approval. Human clinical evidence is limited to observational reports in age-related joint and connective-tissue disorders.

scienceVial: Epithalon) (10 mg | 5 mg/mL

Epitalon

Epitalon (also Epithalon, Epithalamin tetrapeptide) is a synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG) developed by Vladimir Khavinson by directed synthesis from the amino-acid composition of bovine pineal extract Epithalamin [1][2]. It is the most extensively studied of the Khavinson peptide bioregulators, with documented effects on telomerase activation, telomere elongation, melatonin restoration, and lifespan extension in rodent and Drosophila models [3][4][5]. Khavinson and colleagues showed Epitalon activates telomerase in human fetal somatic cell cultures with observable telomere elongation, and Anisimov demonstrated 12–13% lifespan extension in mice and 11–16% in fruit flies [6]. Standard research dosing is 5–10 mg subcutaneously per day for 10–20 consecutive days, repeated 2–3 times yearly. Epitalon is registered as a peptide bioregulator in Russia but is not approved by the FDA, EMA, or MHRA; outside Russia it is a research-only compound. Human clinical evidence is limited to Russian observational use in age-related disorders, with reports of restored circadian melatonin rhythms, improved immune markers, and normalized neuroendocrine function.

scienceVial: 10 mg | 3.33 mg/mL

FOXO4-DRI

FOXO4-DRI is a 43-amino-acid synthetic senolytic peptide developed by Peter de Keizer and colleagues, first described in the landmark Cell 2017 paper as the first peptide-based agent to selectively eliminate senescent cells in mice through targeted disruption of the FOXO4-p53 interaction [1]. The 'DRI' designation reflects its D-retro-inverso engineering: all amino acids are replaced with their D-isomers and the sequence is reversed, producing a peptide highly resistant to enzymatic degradation while preserving target binding [2]. In senescent cells, FOXO4 sequesters p53 in the nucleus and blocks apoptosis; FOXO4-DRI competitively displaces FOXO4 from p53, releasing p53 to trigger intrinsic apoptosis selectively in senescent cells while sparing healthy cells [1][3]. In aged mice, intraperitoneal FOXO4-DRI restored fur density, renal function, and physical fitness. FOXO4-DRI has no human clinical trial data, no FDA or EMA approval, and is sold strictly as a research chemical. Mouse-equivalent doses are 5 mg/kg three times weekly; safe and effective human dosing is unknown.

Livagen

Open Protocolarrow_forward Longevity & Metabolic Support

Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, KEDA) developed by Vladimir Khavinson and colleagues as a tissue-specific bioregulator targeting hepatic tissue and immune function [1][2]. Synthesized by directed analysis of liver and immune-organ peptide preparations, Livagen is one of the better-characterized Khavinson cytogens with documented effects on heterochromatin decondensation in hepatocyte nuclei — a structural manifestation of the broader bioregulator hypothesis that short peptides remodel chromatin to reactivate age-silenced gene programs [3]. Preclinical work shows Livagen normalizes hepatocyte function in aged rats, restores age-impaired protein synthesis programs, and modulates immune gene expression in lymphocytes. Research dosing is 100–500 mcg subcutaneously per day across 10–20 day cycles, or 1–10 mg/day orally in outpatient Russian bioregulator practice, repeated 2–4 times per year. Livagen is registered in Russia under peptide-bioregulator and dietary-supplement legislation but has no FDA, EMA, or MHRA approval. Human clinical evidence is limited to observational use in age-related hepatic and immune disorders.

NAD

science2 vial sizes | 166.7 mg/mL

NAD+ (nicotinamide adenine dinucleotide) is the central redox and signaling cofactor for hundreds of enzymes including sirtuins (SIRT1–7), poly(ADP-ribose) polymerases (PARPs), and CD38, with intracellular concentrations declining substantially with age across human tissues [1][2]. Sinclair, Imai, and colleagues established sirtuins as NAD-dependent deacetylases that regulate longevity, metabolism, and DNA repair, and showed that restoring NAD+ levels through precursor supplementation can reverse age-related metabolic decline in mice [3][4]. Yoshino and colleagues demonstrated in a randomized clinical trial that nicotinamide mononucleotide (NMN) at 250 mg/day improves muscle insulin sensitivity in prediabetic women [5]. NAD+ itself is administered as a research and integrative medicine intervention at 100–500 mg subcutaneously or intramuscularly, or 250–1000 mg by slow intravenous infusion over 1–4 hours, in cycles. NAD+ is sold as a supplement (oral, sublingual, injectable) but the FDA has not approved NAD+ injection for any therapeutic indication. NAD+ precursors (NR, NMN) have FDA NDI status as dietary supplements but are not approved drugs.

Prostamax